The resumption of the rescheduling of elective surgeries as fewer COVID-19 patients are hospitalized, and an aging population, are driving the demand for medical devices. Investors interest in the medical device stocks is evident in the iShares U.S. Medical Devices ETFs (IHI) 2.5% gains over the past three months and 14.5% year-to-date returns.
The integration of advanced technologies and innovative treatments are expected to drive the medical devices industrys growth. According to a Research and Markets report, the global medical devices market is expected to grow at a 6.1% CAGR to $661 billion by 2026.
Given this backdrop, we think it could be wise to bet on fundamentally strong medical device stocks Stryker Corporation (SYK), Edwards Lifesciences Corporation (EW), Boston Scientific Corporation (BSX), and Zimmer Biomet Holdings, Inc. (ZBH). These stocks are rated Buy in our POWR Ratings system.
Click here to checkout our Healthcare Sector Report for 2021
Stryker Corporation (SYK)
Medical technology company SYK operates through three segments: Orthopaedics; MedSurg; and Neurotechnology and Spine. The Kalamazoo, Mich.-based company sells its products to several healthcare facilities through company-owned subsidiaries and third-party dealers globally.
On September 7, 2021, SYK announced its acquisition of Gauss Surgical, a medical device company that developed Triton. Dylan Crotty, president of Strykers Instruments division, said, Our belief is that Triton technology will help improve the industry standards for quantifying blood loss in the labor and delivery department, furthering Strykers commitment to improve safety and outcomes for our caregivers and their patients.
SYKs net sales increased 55.4% year-over-year to $4.29 billion in the second quarter, ended June 30, 2021. Its gross profit came in at $2.77 billion, up 79.1% year-over-year. Its net earnings were $592 million compared to an $83 million loss in the year-ago period. Also, its EPS was $1.55 versus a $0.22 loss in the previous period.
Analysts expect SYKs revenue and EPS to increase 20.5% and 25.4%, respectively, year-over-year to $17.29 billion and $9.32 for its fiscal year 2021. In addition, it has surpassed the consensus EPS estimates in three of the trailing four quarters. Over the past nine months, the stock has gained 8.3% in price to close yesterdays trading session at $262.05.
SYKs strong fundamentals are reflected in its POWR Ratings. The stock has an overall B rating, which indicates a Buy in our proprietary rating system. The POWR Ratings assess stocks by 118 distinct factors, each with its own weighting.
SYK has a B grade for Growth and Stability. Within the Medical Devices & Equipment industry, it is ranked #44 of 182 stocks. Click here to see the additional POWR Ratings for Value, Momentum, Sentiment, and Quality for SYK.
Edwards Lifesciences Corporation (EW)
EW in Irvine, Calif., provides products and technologies for structural heart disease and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. The company distributes its products through a direct sales force and independent distributors.
On July 29, 2021, Michael A. Mussallem, EWs Chairman and CEO, said, Vaccine adoption in key regions has contributed to an increased number of patients seeking and, most importantly, receiving treatment. This quarter, we were pleased that more than 30,000 patients were treated globally with SAPIEN valves, an indication that more patients are benefiting from our life-changing technologies than ever before.
For its fiscal second quarter, ended June 30, 2021, EWs net sales increased 48.8% year-over-year to $1.38 billion. The companys gross profit increased 51.7% from the same period last year to $1.04 billion. Its operating income came in at $542.1 million compared to a $169.7 million loss in the year-ago period. And its EPS was $0.78, versus a $0.20 loss in the previous period.
EWs revenue is expected to be $5.33 billion in fiscal 2021, representing a 21.4% year-over-year rise. The companys EPS is expected to increase 21.5% year-over-year to $2.26 in the current year. It surpassed the Streets EPS estimates in three of the trailing four quarters. Over the past nine months, the stock has gained 26.4% in price to close yesterdays trading session at $111.09.
Its no surprise that EW has an overall B rating, which equates to a Buy in our proprietary rating system. In addition, it has a B grade for Stability and Quality.
EW is ranked #46 in the Medical Devices & Equipment industry. Click here to see the additional POWR Ratings for EW (Growth, Momentum, Value, and Sentiment).
Boston Scientific Corporation (BSX)
BSX develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The Marlborough, Mass.-based company operates through three segments: MedSurg; Rhythm and Neuro; and Cardiovascular.
On October 6, 2021, BSX agreed to acquire Baylis Medical Company Inc. Mike Mahoney, BSXs Chairman and CEO, said, We believe that Baylis Medical Company will add meaningful revenue, operating income, and new research and development capabilities across multiple Boston Scientific businesses, while complementing existing offerings within our electrophysiology and structural heart portfolios.
BSXs net sales increased 53.6% year-over-year to $3.08 billion for its fiscal second quarter, ended June 30, 2021. The companys operating income came in at $262 million, compared to a $71 million loss in the prior year. Its gross profit in the quarter was $2.13 billion, up 75.9% from the year-ago period. And its EPS came in at $0.12 compared to an $0.11 loss per share in the prior years quarter.
For its fiscal year 2021, analysts expect BSXs revenue to be $12 billion, representing a 21.1% year-over-year rise. The companys EPS is expected to increase 67.7% year-over-year to $1.61 in its fiscal year 2021. It surpassed the consensus EPS estimates in three of the trailing four quarters. Over the past nine months, the stock has gained 17.8% in price to close yesterdays trading session at $42.80.
BSXs POWR Ratings reflect this promising outlook. The stock has an overall B rating, which equates to a Buy in our POWR Rating system. Also, the stock has an A grade for Growth.
Click here to see BSXs ratings for Value, Momentum, Stability, Sentiment, and Quality as well. Again, BSX is ranked #33 in the Medical Devices & Equipment industry.
Zimmer Biomet Holdings, Inc. (ZBH)
Warsaw, Ind.-based ZBH, together with its subsidiaries, designs, manufactures and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.
On August 31, 2021, Robert Kraal, Vice President and General Manager, Connected Health at ZBH, said, The introduction of mymobility with Apple Watch underscores Zimmer Biomets commitment to evaluating the real-world clinical benefits of a remote care management platform after orthopedic surgery. These four analyses, utilizing interim data from the ongoing mymobility Clinical Study, suggest that mymobility with Apple Watch may be a viable option to help healthcare professionals monitor how a patient is progressing after surgery and remotely manage rehabilitation regimens to optimize recovery.
ZBHs net sales increased 65.3% year-over-year to $2.03 billion in the second quarter, which ended June 30, 2021. Its operating profit came in at $220.50 million compared to a $171.70 million loss in the previous period. Furthermore, its net earnings were $141.90 million, versus a $206.6 million loss in the year-ago period. Also, its EPS came in at $0.67, compared to a $1 loss in the same period.
For its fiscal year 2021, ZBHs revenue and EPS are expected to grow 15% and 36.9%, respectively, year-over-year to $8.08 billion and $7.76. It surpassed the consensus EPS estimates in each of the trailing four quarters. The stock has gained 9.7% in price since hitting its 52-week low of $130.05 on October 30, 2020, to close yesterdays trading session at $144.97.
ZBHs strong fundamentals are reflected in its POWR ratings. The stock has an overall B rating, which equates to a Buy in our proprietary rating system.
In addition, it has an A grade for Growth, and a B grade for Value. ZBH is ranked #51 in the Medical Devices & Equipment industry. Click here to see the additional POWR Ratings for ZBH (Momentum, Stability, Sentiment, and Quality).
Click here to checkout our Healthcare Sector Report for 2021
SYK shares were trading at $270.13 per share on Tuesday morning, up $8.08 (+3.08%). Year-to-date, SYK has gained 11.06%, versus a 21.54% rise in the benchmark S&P 500 index during the same period.
Riddhima is a financial journalist with a passion for analyzing financial instruments. With a master's degree in economics, she helps investors make informed investment decisions through her insightful commentaries. More...
More here:
SYK: 4 Medical Device Stocks Rated 'Buy' in the POWR Ratings - StockNews.com
- Georgia Tech to Offer Ph.D. in Neuroscience and Neurotechnology, New Minor | News Center - Georgia Tech News Center - May 3rd, 2024 [May 3rd, 2024]
- China developed its very own Neuralink Neucyber brain interface comes from a neurotechnology firm - Tom's Hardware - May 3rd, 2024 [May 3rd, 2024]
- Tether Acquires Majority Stake in Blackrock Neurotech - PYMNTS.com - May 3rd, 2024 [May 3rd, 2024]
- China Shows Off Monkey With Brain Chip Allowing It to Control Robotic Arm - Futurism - May 3rd, 2024 [May 3rd, 2024]
- World must act on neurotech revolution, say experts - The Star Online - May 3rd, 2024 [May 3rd, 2024]
- Opinion | The Fight for Your Kids' Brains Has Already Begun - The New York Times - September 9th, 2023 [September 9th, 2023]
- DEFENDING THE BRAIN | Duke Mag - Duke University - September 9th, 2023 [September 9th, 2023]
- The Innovations and Success of Elon Musk - OPP.Today - September 9th, 2023 [September 9th, 2023]
- Top Companies Using AI to Transform the Healthcare Industry ... - Cryptopolitan - September 9th, 2023 [September 9th, 2023]
- UN Warns Unregulated Neurotechnology Threatens 'Freedom of Thought' - Yahoo News - July 23rd, 2023 [July 23rd, 2023]
- I felt like there was someone in my head, and it wasn't me. - UNESCO - July 23rd, 2023 [July 23rd, 2023]
- Unraveling Connections Between the Brain and Gut - The Good Men Project - July 23rd, 2023 [July 23rd, 2023]
- Neurotechnology: what it is, applications - Iberdrola - February 10th, 2023 [February 10th, 2023]
- Forget Media Manipulation And Misinformation via TikTok And Twitter, Neurotechnology Heralds The New Battle For Our Brains - Forbes - February 10th, 2023 [February 10th, 2023]
- The Jacob Laboratory Translational Neurotechnology - January 2nd, 2023 [January 2nd, 2023]
- Massachusetts Institute Of Technology Experts Come Together In A Play Inspired By Advances In Neurotechnology - India Education Diary - January 2nd, 2023 [January 2nd, 2023]
- Neurotechnologies: The Next Technology Frontier | IEEE Brain - December 18th, 2022 [December 18th, 2022]
- Twelve Neurotechnology Startups to Present at 2022 Neurotech Leaders ... - November 19th, 2022 [November 19th, 2022]
- Research Experience for Undergraduates | Center for Neurotechnology - November 8th, 2022 [November 8th, 2022]
- Axoft Launches Brain Implant Technology to Treat Long-Term Neurological Disorders and is Granted FDA Breakthrough Device Designation - Business Wire - October 19th, 2022 [October 19th, 2022]
- Researcher combines AI and microelectronics to create neural implants that fight brain disorders - University of Toronto - October 19th, 2022 [October 19th, 2022]
- Global Contactless Biometrics Technology Market Size And Forecast | Aware Inc., Fingerprint Cards AB, Fujitsu Limited, Gemalto N.V., HID Global,... - October 19th, 2022 [October 19th, 2022]
- Facial Recognition Market Size and Share 2022 | Global Industry Analysis, Feasibility Study and Development Scope by 2032 | NEC Corporation (NEC)... - October 17th, 2022 [October 17th, 2022]
- Pitt scientists awarded $8 million for neurotechnology to restore arm and hand movements after strokes - University of Pittsburgh - October 15th, 2022 [October 15th, 2022]
- UN: Highlights from the 51st Session of the Human Rights Council - ARTICLE 19 - Article 19 - October 15th, 2022 [October 15th, 2022]
- PD Neurotechnology, a MedTech start-up for patients suffering from ... - October 8th, 2022 [October 8th, 2022]
- Brain ScienceConsciousness as the Property of Thought | Neurotech - VGR.com - October 6th, 2022 [October 6th, 2022]
- Facial Recognition Technology Market to witness a substantial growth owing to rising adoption of technology till 2032 | NEC Corporation, Aware,... - October 6th, 2022 [October 6th, 2022]
- ARC Future Fellowships awarded to Turner Institute researchers - Monash University - September 17th, 2022 [September 17th, 2022]
- Critics Picks: Cate Blanchett, Steven Spielberg Films Among the 15 Best of the Fall Festivals - Hollywood Reporter - September 17th, 2022 [September 17th, 2022]
- Stryker Launches Pulse Intelligent Delivery Platform at the 2022 American Orthopaedic Foot & Ankle Society Annual Meeting - Business Wire - September 17th, 2022 [September 17th, 2022]
- If separating conjoined twins results in death, which one should die? - Big Think - September 17th, 2022 [September 17th, 2022]
- Theater of Thought Review: Werner Herzog Crafts a Bracing Exploration of Neurotechnology and Consciousness - Hollywood Reporter - September 7th, 2022 [September 7th, 2022]
- Elon Musk seeks to expand his empire in the world of neurotechnology - Gearrice - September 7th, 2022 [September 7th, 2022]
- VoxNeuro Announces Collaboration with Boston University and Launch of Clinical Studies Focusing on Concussion and Alzheimers Disease - Yahoo Finance - September 7th, 2022 [September 7th, 2022]
- Tri-anim Health Services announces exclusive relationship to distribute BrainScope's breakthrough technology for mild head injury including... - September 7th, 2022 [September 7th, 2022]
- Interaxon Inc. (Muse) Highlights Myndlifts Preliminary Study and the Benefit of Partnerships for Digital Therapeutics Research - BioSpace - September 7th, 2022 [September 7th, 2022]
- Elon Musk and Neuralink executive Shivon Zilis reportedly conceived twins via IVF - The Independent - August 29th, 2022 [August 29th, 2022]
- Biometric Wearable Market Research Insights with Trends, Competitive Analysis, Opportunities, Forecast 2022 to 2030 Muleskinner - Muleskinner - August 29th, 2022 [August 29th, 2022]
- Neurotechnology - the future of the legal profession? - Lexology - August 25th, 2022 [August 25th, 2022]
- Future criminals could be monitored by chips in their brains, experts claim... - The US Sun - August 25th, 2022 [August 25th, 2022]
- Stryker to participate in the 2022 Wells Fargo Securities Healthcare Conference - GuruFocus.com - August 25th, 2022 [August 25th, 2022]
- Investing in Brain Research and Neuroengineering - University of Houston - August 2nd, 2022 [August 2nd, 2022]
- Hamilton-based Zentrela working to understand the cannabis experience - Hamilton Spectator - August 2nd, 2022 [August 2nd, 2022]
- IntualityAI may be Able to Provide Psychotherapy for Robots in Future - AZoRobotics - August 2nd, 2022 [August 2nd, 2022]
- Coconuts, Corporations: On Vauhini Vara's The Immortal King Rao - lareviewofbooks - August 2nd, 2022 [August 2nd, 2022]
- MindMaze Enters New Strategic Partnership with Alfa Romeo F1 Team ORLEN to Advance Technologies for Brain Health, Safety, and Performance - Yahoo... - July 13th, 2022 [July 13th, 2022]
- MindMaze Receives Recognition as one of Switzerland's Best Managed Companies - Business Wire - July 13th, 2022 [July 13th, 2022]
- OpenBCI and Varjo Partner to Bring Neurotechnology to Spatial Computing - July 11th, 2022 [July 11th, 2022]
- Three top technologies taking healthcare by storm - Kalkine Media - July 11th, 2022 [July 11th, 2022]
- It is time to leverage technology to correct the challenges people have with their minds: Antano Solar, CE.. - ETHealthWorld - July 11th, 2022 [July 11th, 2022]
- Elon Musk Secretly Fathered Twins With His Company's Executive: Report - KFI AM 640 - July 11th, 2022 [July 11th, 2022]
- Stryker to host conference call on July 26, 2022 - GuruFocus.com - July 11th, 2022 [July 11th, 2022]
- Neurotechnology Announces MOSIP Integration and Support in MegaMatcher SDK and ABIS - PR Newswire - June 15th, 2022 [June 15th, 2022]
- Musk's Twitter $44 Billion Bid Includes Financier Close to Russia - Report By Investing.com - Investing.com - June 15th, 2022 [June 15th, 2022]
- Stryker Strengthens Its R&D Capabilities with Advanced Global Technology Center - Press Trust of India - Press Trust of India - June 9th, 2022 [June 9th, 2022]
- Cuba is the only nation with a governmental science and technology program on the brain - Granma English - June 9th, 2022 [June 9th, 2022]
- 3 Disruptive Tech Stocks to Go All In on Now - InvestorPlace - June 9th, 2022 [June 9th, 2022]
- OpenBCI and Varjo Partner to Bring Neurotechnology to Spatial Computing - PR Newswire - June 5th, 2022 [June 5th, 2022]
- 3D Reconstruction Technology Market Size, Scope and Forecast | 3D Reconstruction, Eos Systems Inc., Everest Innovation Technology, Microsoft, NAVVIS,... - June 5th, 2022 [June 5th, 2022]
- Fingerprint Biometrics in the VAR Market to Eyewitness Massive Growth by 2031 The Greater Binghamton Business Journal - The Greater Binghamton... - June 5th, 2022 [June 5th, 2022]
- Horrors of Elon Musks Neuralink REVEALED including brain hacking technology and animal deaths... - The Scottish Sun - May 25th, 2022 [May 25th, 2022]
- Stryker Co. (NYSE:SYK) Receives Consensus Rating of Buy from Brokerages - Defense World - May 25th, 2022 [May 25th, 2022]
- Evon Medics, LLC Has Been Awarded $2.8 Million Grant for the Development and Evaluation of its Mobile Health Platform for Remote Management of... - May 11th, 2022 [May 11th, 2022]
- Mobile Biometrics Market Analysis by Size, Business Strategies, Share, Growth, Trends, Revenue, Competitive Landscape and Developments Forecast by... - May 11th, 2022 [May 11th, 2022]
- Dubai on the Brain: NeuroVigil's Philip Low Assembles ... - May 6th, 2022 [May 6th, 2022]
- Research Associate: Participatory Research and Communications Officer job with KINGS COLLEGE LONDON | 292429 - Times Higher Education - May 6th, 2022 [May 6th, 2022]
- Face Recognition Software Market 2022: Size, Industry Share, Approaches, and Forecast By 2028, (Idemia (FR), Aware (US), Leidos (US), BioID (DE)) ... - May 6th, 2022 [May 6th, 2022]
- Stocktake: Investors wary on Musk's Twitter deal - The Irish Times - May 6th, 2022 [May 6th, 2022]
- Hydrocolloid Dressing Market Competitive Landscape Analysis With Forecast by 2027 - BioSpace - May 6th, 2022 [May 6th, 2022]
- Futuristics Overview of Neural Control Market: Industry Insights and Forecast 2022-2028 by MIT, Hebrew university, Haier, Neurotechnology,,, and more... - May 3rd, 2022 [May 3rd, 2022]
- Brain Computer Interface (BCI) Market Poised to Garner a Valuation of USD 5.48 Billion by 2030, Growing at a 14.72% CAGR - Report by Market Research... - May 3rd, 2022 [May 3rd, 2022]
- Stryker's InSpace subacromial balloon spacer two-year, Level 1 randomized controlled clinical study published in the Journal of Bone and Joint Surgery... - May 3rd, 2022 [May 3rd, 2022]
- Stryker to participate in the Bank of America Securities 2022 Health Care Conference - Benzinga - Benzinga - May 3rd, 2022 [May 3rd, 2022]
- Earnings week 2: Supply chain shortages slowed ResMed, other medtechs from meeting demand - MedTech Dive - May 3rd, 2022 [May 3rd, 2022]
- Mind-reading technology Are we ready for it? - Freethink - April 25th, 2022 [April 25th, 2022]
- The brain implant that can translate your thoughts into text - SBS News - April 15th, 2022 [April 15th, 2022]
- Stryker says 88 jobs to be eliminated in May, part of previously announced layoff schedule - The Ledger - April 15th, 2022 [April 15th, 2022]
- Moon Rabbit Collaborates with Foresight Institute to Speed Up Life Extension Research - CryptoNewsZ - April 4th, 2022 [April 4th, 2022]
- Cybin Announces Initiation of Kernel Flow Feasibility Study Measuring Psychedelic Effects on the Brain - Business Wire - April 4th, 2022 [April 4th, 2022]